BringCom’s Post

This is great news! Tuberculosis is included in the shortlist for the vaccine investment strategy at GAVI, meaning that we are one step closer to getting vaccines into the hands of those who need them. Potential TB vaccines are still a few years away, but being prepared is the first step to success! And the investment into local manufacturing will create much needed progress on that front as well! #TB #pandemicpreparedness #GAVI #localization https://lnkd.in/dUZ9FgR6

++ 𝐄𝐱𝐩𝐚𝐧𝐝𝐞𝐝 𝐁𝐢𝐨𝐍𝐓𝐞𝐜𝐡-𝐂𝐄𝐏𝐈 𝐩𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩 𝐭𝐨 𝐬𝐭𝐫𝐞𝐧𝐠𝐭𝐡𝐞𝐧 𝐀𝐟𝐫𝐢𝐜𝐚’𝐬 𝐦𝐑𝐍𝐀 𝐯𝐚𝐜𝐜𝐢𝐧𝐞 𝐞𝐜𝐨𝐬𝐲𝐬𝐭𝐞𝐦 +++ Today we announced an expanded partnership with CEPI (Coalition for Epidemic Preparedness Innovations) to broaden the scope of our manufacturing facility in Africa. With this we also want to support the entire spectrum – from local research and clinical trials to commercial production.  🌍 𝐂𝐨𝐧𝐭𝐫𝐢𝐛𝐮𝐭𝐢𝐧𝐠 𝐭𝐨 𝐞𝐪𝐮𝐢𝐭𝐚𝐛𝐥𝐞 𝐚𝐜𝐜𝐞𝐬𝐬 𝐭𝐨 𝐧𝐨𝐯𝐞𝐥 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞𝐬: BioNTech and CEPI commit to enabling equitable access, including affordable pricing to select vaccines produced at BioNTech’s facility in Kigali, with priority access to African countries. 🛡 𝐖𝐨𝐫𝐤𝐢𝐧𝐠 𝐣𝐨𝐢𝐧𝐭𝐥𝐲 𝐨𝐧 𝐀𝐟𝐫𝐢𝐜𝐚’𝐬 𝐩𝐚𝐧𝐝𝐞𝐦𝐢𝐜 𝐩𝐫𝐞𝐩𝐚𝐫𝐞𝐝𝐧𝐞𝐬𝐬: In the event of a disease outbreak, BioNTech would dedicate up to half of the facility’s manufacturing capacity to produce emergency response mRNA vaccines, subject to regulatory authorization.  🥼 𝐒𝐮𝐩𝐩𝐨𝐫𝐭𝐢𝐧𝐠 𝐭𝐡𝐞 𝐦𝐑𝐍𝐀 𝐯𝐚𝐜𝐜𝐢𝐧𝐞 𝐞𝐜𝐨𝐬𝐲𝐬𝐭𝐞𝐦 𝐢𝐧 𝐀𝐟𝐫𝐢𝐜𝐚: BioNTech will dedicate manufacturing capacities to third party projects aimed at enabling R&D activities for novel mRNA-based vaccine candidates against pathogens with epidemic or pandemic potential. We are thankful for the trust put in us by various partners and collaborators. Our joint efforts are aimed at supporting the African Union’s and Africa CDC's goal of producing 60 percent of total vaccine doses required on the continent by 2040. 𝑳𝒊𝒏𝒌 𝒕𝒐 𝒑𝒓𝒆𝒔𝒔 𝒓𝒆𝒍𝒆𝒂𝒔𝒆 𝒂𝒏𝒅 𝒇𝒐𝒓𝒘𝒂𝒓𝒅-𝒍𝒐𝒐𝒌𝒊𝒏𝒈 𝒔𝒕𝒂𝒕𝒆𝒎𝒆𝒏𝒕𝒔: https://lnkd.in/evyfhEYs  

This just in!!! 📰 🌍 💉   The Gavi Board announced today a game-changing initiative: the African Vaccine Manufacturing Accelerator (AVMA). AVMA is set to allocate up to US$ 1 billion, empowering sustainable vaccine manufacturing in Africa. This initiative includes the commitment to turning pandemic lessons into action with the establishment of a US$ 500 million First Response Fund, ensuring immediate financing for vaccine response in future pandemics and support for countries to close routine immunisation gaps created during the pandemic. Additionally, more than US$ 1.8 billion has been approved to bolster African vaccine manufacturing, reach missed children, and fortify pandemic preparedness. "These decisions allow our Alliance to continue to execute on our core mission, expanding access to lifesaving vaccines. Gavi can now make these new innovations available to the lower-income countries that need them the most, helping protect millions more against deadly infectious diseases." shared David Marlow, CEO of Gavi, the Vaccine Alliance. #SAHTAC celebrates this monumental step toward a healthier, more resilient world! #VaccineAlliance #HealthForAll #GlobalHealth Rare Diseases South Africa Desmond Tutu Health Foundation WACI Health South African Tuberculosis Vaccine Initiative (SATVI) International Partnership for Microbicides PATH Campaigning for Cancer Treatment Action Campaign (TAC)

This week’s Gavi Board meeting in Accra placed a strong focus on helping lower-income countries tackle backsliding from the #COVID19 pandemic and be better prepared to tackle future health emergencies:  As our Board Chair José Manuel Barroso said, 2024 will be a “pivotal year for the Vaccine Alliance.” From funding to reach #zerodosechildren & support the #BigCatchUp, to financing to rapidly respond to future pandemics, this was an important set of decisions to help face some of global health’s biggest challenges.  The board also approved the inclusion of the new multivalent meningococcal vaccine into the Gavi portfolio, as well as the shortlist of vaccines for Gavi’s next Vaccine Investment Strategy including tuberculosis, group B strep, shigella and dengue.  “These decisions allow our Alliance to continue to expand access to lifesaving vaccines. Gavi can now make these new innovations available to the lower-income countries that need them the most, helping protect millions more against infectious diseases" - Gavi CEO David M.. 

#Lancet #MalariaVaccine #2Candidates #RTS,S/AS01 #R21Matrix-M A key finding in 2021 was the #successful demonstration of programmatic #feasibility, #effectiveness, and #safety of #RTS,S/AS01 in very large #pilot implementations in three African countries. Demand for #malaria #vaccines is unprecedented, with #18countries already #approved for #Gavi, the Vaccine Alliance support for vaccine introduction in 2024. However, #supply of RTS,S/AS01 is severely #constrained, with only 18 million doses available between 2023 and 2025, and the annual demand is anticipated to be around 80–100 million doses. #Inventors at the University of Oxford (#Oxford, UK), in partnership with the #SerumInstitute of India (Pune, India), have now #developed a second, #circumsporozoite-based #vaccine similar in construct to RTS,S/AS01, known as #R21Matrix-M. Like RTS,S/AS01, the R21/Matrix-M vaccine targets the circumsporozoite antigen. The #SerumInstitute of #India has a track record of #supplying other WHO-recommended vaccines at very #largescale, at relatively #lowcost, and of meeting WHO's prequalification standards on vaccine quality, safety, and efficacy. https://lnkd.in/gUX9aEYw

New Post: More Than $1.8 Billion In Support For African Vaccine Manufacturing   - https://lnkd.in/enGwyccq Than $1.8 Billion In Support For African Vaccine Manufacturing  https://lnkd.in/eQGZEcad – The Board of Gavi, the Vaccine Alliance today announced a series of decisions that will help lower-income countries tackle backsliding from the COVID-19 pandemic and be better prepared to respond to US future health emergencies. Needle Geneva/Accra// – The Board of Gavi, the Vaccine Alliance today announced a series of decisions that will help lower-income countries tackle backsliding from the COVID-19 pandemic and be better prepared to respond to US future health emergencies. The decisions were taken during a two-day meeting hosted by the Government of Ghana in Accra, Ghana, from 6-7 December. Concrete action in support of African vaccine manufacturing, future pandemic response Following more than 18 months of close collaboration between Gavi, the African Union and Africa CDC, the Board today approved the establishment of the African Vaccine Manufacturing Accelerator (AVMA). AVMA is an innovative financing mechanism aimed at establishing a sustainable African vaccine manufacturing industry capable of improving the region’s resilience in the face of pandemics, outbreaks and other health emergencies as well as the health of global vaccine markets. AVMA was designed through an extensive consultation process that involved partners, donors, industry, civil society, and others. Gavi, as one of the largest purchasers of vaccines in the world, is thus sending a powerful signal to global markets that it will support African vaccine manufacturing. AVMA aims to make up to US$ 1 billion available to manufacturers at key moments in the development process as a way of helping offset high start-up costs and provide assurance of demand. By focusing on “priority” antigens, product profiles, and vaccine platforms, as well as constructing clear incentives for both “fill and finish” and drug substance production, AVMA will also support global vaccine markets by targeting clear unmet needs and help establish a thriving, sustainable, end-to-end African vaccine manufacturing ecosystem. AVMA is the final pillar of Gavi’s regional manufacturing strategy, with the first three pillars approved by the Board in December 2022. With this Board approval, Gavi can now consult widely on the final operational framework for AVMA, including the establishment of an inclusive steering committee, and processes for governance, monitoring and course-correcting as needed. These final pieces will be reviewed by the Board in June 2024, following which AVMA will be officially launched in that same month during an event co-hosted by France and Africa CDC, alongside European and internationa

Gavi has gone from providing support for vaccines against six infectious diseases in 2000 to 19 in 2022! But how do we decide which vaccines to invest in? From consulting experts from around the world to decisions by the Gavi Board, learn about the process: The vaccine landscape is becoming increasingly complex. The latest Vaccine Investment Strategy has been updated to reflect the challenges posed by antimicrobial resistance and #climatechange: The Vaccine Investment Strategy enables Gavi to maximise the number of lives it helps save and the number of people whose health it improves, and facilitates long‑term planning for partners, donors, manufacturers and Gavi‑implementing countries.

📣 We’ve today announced new research to expand access to the world’s first Chikungunya vaccine in outbreak-affected countries. The clinical trials, funded by CEPI and the European Union Horizon Europe programme, will help generate additional data to potentially support licensure of Valneva's #Chikungunya vaccine in endemic countries and at-risk populations, such as children and pregnant women. Several thousand participants are set to take part in the planned trials, due to start in 2025. Some trials are planned to be conducted in Brazil, which is currently facing a significant Chikungunya outbreak with over 340,000 cases reported so far this year. Through the CEPI-EU partnership, Valneva are already working with Brazil’s Instituto Butantan who are committed to developing and producing the Chikungunya vaccine at an affordable price for distribution in Latin American countries. CEPI-EU funding will also support technology transfer of the vaccine drug product to an additional vaccine manufacturer to accelerate and expand access to IXCHIQ® in low- and middle-income countries in Asia that are vulnerable to chikungunya outbreaks. More ⬇

New Post: More Than $1.8 Billion In Support For African Vaccine Manufacturing   - https://lnkd.in/eVWDWPcK Than $1.8 Billion In Support For African Vaccine Manufacturing  https://lnkd.in/e5qH6cjz – The Board of Gavi, the Vaccine Alliance today announced a series of decisions that will help lower-income countries tackle backsliding from the COVID-19 pandemic and be better prepared to respond to US future health emergencies. Needle Geneva/Accra// – The Board of Gavi, the Vaccine Alliance today announced a series of decisions that will help lower-income countries tackle backsliding from the COVID-19 pandemic and be better prepared to respond to US future health emergencies. The decisions were taken during a two-day meeting hosted by the Government of Ghana in Accra, Ghana, from 6-7 December. Concrete action in support of African vaccine manufacturing, future pandemic response Following more than 18 months of close collaboration between Gavi, the African Union and Africa CDC, the Board today approved the establishment of the African Vaccine Manufacturing Accelerator (AVMA). AVMA is an innovative financing mechanism aimed at establishing a sustainable African vaccine manufacturing industry capable of improving the region’s resilience in the face of pandemics, outbreaks and other health emergencies as well as the health of global vaccine markets. AVMA was designed through an extensive consultation process that involved partners, donors, industry, civil society, and others. Gavi, as one of the largest purchasers of vaccines in the world, is thus sending a powerful signal to global markets that it will support African vaccine manufacturing. AVMA aims to make up to US$ 1 billion available to manufacturers at key moments in the development process as a way of helping offset high start-up costs and provide assurance of demand. By focusing on “priority” antigens, product profiles, and vaccine platforms, as well as constructing clear incentives for both “fill and finish” and drug substance production, AVMA will also support global vaccine markets by targeting clear unmet needs and help establish a thriving, sustainable, end-to-end African vaccine manufacturing ecosystem. AVMA is the final pillar of Gavi’s regional manufacturing strategy, with the first three pillars approved by the Board in December 2022. With this Board approval, Gavi can now consult widely on the final operational framework for AVMA, including the establishment of an inclusive steering committee, and processes for governance, monitoring and course-correcting as needed. These final pieces will be reviewed by the Board in June 2024, following which AVMA will be officially launched in that same month during an event co-hosted by France and Africa CDC, alongside European and internationa

🌍 𝗧𝗵𝗲 𝗔𝗳𝗿𝗶𝗰𝗮𝗻 𝗩𝗮𝗰𝗰𝗶𝗻𝗲 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝗜𝗻𝗶𝘁𝗶𝗮𝘁𝗶𝘃𝗲 𝗼𝗳 𝟮𝟬𝟯𝟬 - 𝗬𝗼𝘂𝗿 𝗢𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝘆 𝘁𝗼 𝗠𝗮𝗸𝗲 𝗮 𝗗𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝗰𝗲! 🌱 Today, I would like to shed light about the African Vaccine Manufacturing Initiative of 2030, launched by Africa CDC (Centers for Disease Control and Prevention). 𝑺𝒐, 𝒘𝒉𝒂𝒕 𝒆𝒙𝒂𝒄𝒕𝒍𝒚 𝒊𝒔 𝒕𝒉𝒊𝒔 𝒊𝒏𝒊𝒕𝒊𝒂𝒕𝒊𝒗𝒆 𝒂𝒃𝒐𝒖𝒕? The goal of the African Vaccine Manufacturing Initiative (AVMI) is to establish a sustainable vaccine manufacturing industry in Africa. With support from The Global Vaccine Alliance (GAVI) Board, AVMI aims to make up to US$ 1 billion available to support vaccine manufacturing across the continent. This is an incredible opportunity for Africa to become self-reliant in vaccine production and ensure access to critical vaccines, even in times of health emergencies. The AVMI has set ambitious goals for the African vaccine manufacturing industry. The Partnerships for African Vaccine Manufacturing (PAVM), established by the African Union Heads of States and Governments, aims to develop, produce, and supply over 60% of the total vaccine doses required on the continent by 2040. This is a significant increase from the current less than 1% production rate. 𝑾𝒉𝒚 𝒊𝒔 𝒕𝒉𝒆 𝒊𝒏𝒗𝒐𝒍𝒗𝒆𝒎𝒆𝒏𝒕 𝒐𝒇 𝒚𝒐𝒖𝒕𝒉 𝒄𝒓𝒖𝒄𝒊𝒂𝒍 𝒕𝒐 𝒕𝒉𝒆 𝒔𝒖𝒄𝒄𝒆𝒔𝒔 𝒐𝒇 𝒕𝒉𝒊𝒔 𝒊𝒏𝒊𝒕𝒊𝒂𝒕𝒊𝒗𝒆? 🙋♀️ Well, let me share a powerful anecdote with you. During the Ebola outbreak in West Africa, it was the young researchers, scientists, and healthcare professionals who worked tirelessly to develop treatments and find solutions. Youthfulness brings fresh perspectives, innovative ideas, and a relentless drive to make a difference. We, the young generation, are not just the future of tomorrow; we are the voices that need to be heard today! That is why I want to appeal to influential leaders of global health, such as Jean Kaseya, the Director of Africa CDC and the pioneer of this initiative, and Dr Ebere Okereke, the CEO of the Africa Public Health Foundation, to prioritize the involvement of youth (15-35) as defined by the UN in this incredible initiative. Our skills, passions, and enthusiasm can truly propel the African vaccine manufacturing industry forward and ensure a brighter and healthier future for our continent. Aspiring to have a career in vaccinology as I wish? This is your chance to shine! 🌟 By getting involved in AVMI, you can contribute to groundbreaking research, manufacturing processes, and distribution strategies. The AVMA will be a catalyst for such opportunities, and it is up to us to seize them. Embrace the challenge, engage in dialogue, and actively participate in shaping the future of African vaccine manufacturing. Remember, the power to bring about change lies in our hands. Happy 7th Birthday Africa CDC #AVMI2030 #YouthInScience #HealthSecurity #AfricaCDC #AfricanUnion #GlobalHealthLeaders